Abstract
SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have